AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12768300
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue (goserelin 3.6 mg, every 28 days)
Trial: 10376918
Drug: edrophonium HCl
DrugBank: Edrophonium (DB01010)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: edrophonium HCl (12 to 18 mg)
Trial: 2066823
Drug: Poster intervention
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poster intervention group (weekly tracking with poster)
Trial: 2066823
Drug: Poster/postcard intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poster/postcard intervention group (weekly tracking with poster and postcard reminders)
Trial: 6799196
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) during ProMACE-MOPP treatment
Trial: 6799196
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet during ProMACE-MOPP treatment
Trial: 6799196
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) as an adjunct to chemotherapy or chemotherapy plus total body irradiation
Trial: 6799196
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet as an adjunct to chemotherapy or chemotherapy plus total body irradiation
Trial: 31941354
Drug: Intravenous Amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Amiodarone
Trial: 30004914
Drug: Intravenous Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Lidocaine
Trial: 31941354
Drug: Intravenous Drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Drugs (Amiodarone or Lidocaine)
Trial: 31941354
Drug: Intraosseous Drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous Drugs (Amiodarone or Lidocaine)
Trial: 31941354
Drug: Placebo (Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Intravenous and Intraosseous)
Trial: 10325486
Drug: 0.1% adapalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% adapalene gel
Trial: 26226999
Drug: Ranolazine 750
RxNorm normalized name: Ranolazine 750 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 750 mg BID and Dronedarone 225 mg BID
Trial: 26226999
Drug: Ranolazine 750
RxNorm normalized name: Ranolazine 750 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 750 mg BID and Dronedarone 150 mg BID
Trial: 26226999
Drug: Ranolazine alone
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine alone (750 mg BID)
Trial: 26226999
Drug: Dronedarone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone alone (225 mg BID)
Trial: 22229650
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with propofol and remifentanil
Trial: 19208440
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate and GTN spray (group A)
Trial: 19208440
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug and GTN spray (group B)
Trial: 19208440
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate and placebo spray (group C)
Trial: 19208440
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug and placebo spray (group D)
Trial: 17890876
Drug: Intravenous EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous EPO
Trial: 17163894
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of providing information and behavioral skills training
Trial: 9278201
Drug: Prednisolone and
RxNorm normalized name: prednisolone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone and Niacin combination
Trial: 9278201
Drug: Chloroquine (2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (2.1 g base total dose) with Prednisolone
Trial: 9278201
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with Prednisolone
Trial: 3105310
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g of carbohydrate in an isocaloric diet
Trial: 3105310
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of carbohydrate in an isocaloric diet
Trial: 29607766
Drug: FAIS-specific physical
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAIS-specific physical therapy group received personalized progressive strengthening and functional retraining.
Trial: 22266043
Drug: Single-agent pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent pemetrexed
Trial: 24486883
Drug: LY545694 (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY545694 (25mg twice daily)
Trial: 24486883
Drug: Gabapentin (600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600mg 8 hours apart; 6 doses over 3 days)
Trial: 22221173
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ursodeoxycholic acid (UDCA) at 17-23 mg/kg/day
Trial: 22221173
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ursodeoxycholic acid (UDCA)
Trial: 20556559
Drug: Flavocoxid (569
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavocoxid (569 mg HED)
Trial: 20556559
Drug: Flavocoxid combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavocoxid combined with aspirin (370 mg HED)
Trial: 2123065
Drug: Mild induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild induction chemotherapy in patients aged greater than or equal to 70 and/or with concurrent nonhematologic disorders (28 patients)
Trial: 2123065
Drug: Conventional induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional induction chemotherapy in eligible patients (52 patients)
Trial: 2123065
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care alone in patients not suitable for induction chemotherapy (23 patients)
Trial: 30672195
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Hegu needling and Shu needling techniques at the positive reaction points
Trial: 11960953
Drug: Tyramine infusion
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine infusion
Trial: 17507322
Drug: etravirine 800
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: etravirine 800 mg bid
Trial: 17507322
Drug: etravirine 400
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: etravirine 400 mg bid
Trial: 16286387
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral corticosteroids (CS) used by 13 RA patients
Trial: 16286387
Drug: No corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No corticosteroid treatment (RA patients without CS and healthy controls)
Trial: 12401595
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl (10 micro g/kg bolus followed by 10 micro g. kg(‐1). h(‐1) infusion)
Trial: 12401595
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl (2 micro g/kg)
Trial: 12401595
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl (10 micro g/kg bolus and 10 micro g. kg(‐1). h(‐1))
Trial: 2297150
Drug: Metaproterenol (Alupent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (Alupent inhalation solution)
Trial: 6125394
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily doses of clobazam
Trial: 6125394
Drug: Divided daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided daily doses of clobazam
Trial: 29576505
Drug: Siponimod 2
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siponimod 2 mg once daily
Trial: 25029702
Drug: Dairy meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy meal (3 servings providing 1350 mg calcium)
Trial: 19580368
Drug: Inhaled cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cyclosporine (ACsA) 300 mg, 3 days a week for 2 years
Trial: 19580368
Drug: Inhaled cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cyclosporine (ACsA)
Trial: 16750618
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy with SM (15 mg/kg intramuscularly three times per week for the initial 3 months)
Trial: 16750618
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy without SM
Trial: 16750618
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy with SM
Trial: 16246987
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance (CrCl) of 30 mL/min or lower (<= 0.50 mL/s)
Trial: 16246987
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance (CrCl) higher than 90 mL/min (> 1.50 mL/s)
Trial: 16246987
Drug: Participants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with CrCl of 30 mL/min or lower (<= 0.50 mL/s)
Trial: 16246987
Drug: Moderate kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate kidney impairment (CrCl between 30 mL/min and 90 mL/min)
Trial: 28432376
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg MDMA
Trial: 18794647
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg MDMA
Trial: 2084208
Drug: Cavit-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavit-G
Trial: 27034623
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g CrN (CrN-Low)
Trial: 27034623
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g CrN (CrN-High)
Trial: 27034623
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g CrM
Trial: 18830857
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg for 24 weeks
Trial: 18830857
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg and 8 mg)
Trial: 16647684
Drug: 3-day hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day hormone free interval (HFI)
Trial: 16647684
Drug: Continuing active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing active pills
Trial: 16647684
Drug: 21/7-day pre-extension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21/7-day pre-extension cycle with heavier daily flow ratings
Trial: 16647684
Drug: 21/7-day pre-extension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21/7-day pre-extension cycle with lighter daily flow ratings
Trial: 14659770
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 4IU every other day for 3 months
Trial: 9491200
Drug: Dpt rush
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dpt rush immunotherapy
Trial: 8412148
Drug: Alcohol (0.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.32 ml/kg)
Trial: 25330837
Drug: DHEA 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 75 mg daily for three consecutive menstrual cycles prior to IVF cycles
Trial: 25330837
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no DHEA treatment)
Trial: 16700374
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with carbamazepine (Group A, n = 16)
Trial: 16700374
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with carbamazepine and phenytoin (Group B, n = 16)
Trial: 16700374
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (Group C, n = 18)
Trial: 12853784
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) 1 gm twice daily
Trial: 6087129
Drug: Cholecystokinin-octapeptide (CCK-OP)
RxNorm normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholecystokinin-octapeptide (CCK-OP) treatment: 1 mg/ml solution, two drops, three times daily for one month
Trial: 6087129
Drug: Soy flour
RxNorm normalized name: soy flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy flour treatment: 30 gm, three times daily for one month
Trial: 6087129
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CCK-OP and soy flour treatments
Trial: 24861828
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral 17β-estradiol (0.5 mg/d)
Trial: 24861828
Drug: Low-dose venlafaxine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose venlafaxine hydrochloride extended release (75 mg/d)
Trial: 18536860
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mcg once daily
Trial: 18060091
Drug: Placebo (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (usual care minus inhaled anticholinergics)
Trial: 10335761
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 40 mg twice daily
Trial: 12828751
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 60 mg twice daily
Trial: 10335761
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 120 mg twice daily
Trial: 10335761
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 240 mg twice daily
Trial: 10335761
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 60 mg twice daily for 6 months
Trial: 10335761
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 80 mg twice daily for 3 months
Trial: 10335761
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 240 mg once daily for 12 months
Trial: 10335761
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl (various doses)
Trial: 7785008
Drug: Expiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expiratory muscle training (EMT) for 15 minutes twice daily for four weeks using a pressure threshold device; expiratory threshold set at 30% of PEmax.
Trial: 4081404
Drug: Nalidixic acid
RxNorm normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalidixic acid (1 g X 3)
Trial: 4081404
Drug: Pivmecillinam (200‐400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam (200‐400 mg X 3)
Trial: 27163502
Drug: FF/LEVO (100/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/LEVO (100/200 μg) as a fixed-dose combination (FDC)
Trial: 27163502
Drug: FF (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF (110 μg)
Trial: 27163502
Drug: LEVO (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEVO (200 μg)
Trial: 20547984
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) 20 mg/m²/d plus chemotherapy (cisplatin and paclitaxel)
Trial: 20547984
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (cisplatin and paclitaxel)
Trial: 20547984
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) plus chemotherapy (cisplatin and paclitaxel)
Trial: 16061839
Drug: Hydroalcoholic 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroalcoholic 2.5% testosterone gel applied to scrotal skin (1 g, n = 54)
Trial: 16061839
Drug: Hydroalcoholic 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroalcoholic 2.5% testosterone gel applied to non-scrotal skin (5 g, n = 56)
Trial: 16061839
Drug: Androderm patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androderm patches (2 patches/day, n = 52)
Trial: 16061839
Drug: Hydroalcoholic 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroalcoholic 2.5% testosterone gel (scrotal and non-scrotal)
Trial: 16061839
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (scrotal gel, non-scrotal gel, patch)
Trial: 3286040
Drug: Aspirin, 325
RxNorm normalized name: Aspirin, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 325 mg daily
Trial: 3286040
Drug: Aspirin, 325
RxNorm normalized name: Aspirin, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 325 mg three times daily
Trial: 3286040
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily)
Trial: 2680158
Drug: Sulfinpyrazone (267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfinpyrazone (267 mg three times daily)
Trial: 15811142
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three times daily)
Trial: 3286040
Drug: Aspirin daily
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin daily
Trial: 3286040
Drug: Aspirin three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin three times daily
Trial: 3286040
Drug: All aspirin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All aspirin-containing regimens
Trial: 30778004
Drug: ILSM and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILSM and metformin (ILSM+Met)
Trial: 27734980
Drug: Steroids +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids + Kabat physical rehabilitation
Trial: 24518152
Drug: High-dose grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose grape seed extract (200 mg/d)
Trial: 24518152
Drug: Low-dose grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose grape seed extract (100 mg/d)
Trial: 23329572
Drug: Transplantation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplantation of autologous mesenchymal stem cells (MSCs) from G-CSF-mobilised peripheral blood
Trial: 20826993
Drug: Narrow-band UV-B
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UV-B (TL-01) phototherapy, twice-weekly for 3 months
Trial: 20826993
Drug: Oral 8-Methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 8-Methoxsalen PUVA, twice-weekly for 3 months